Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
762.100.5%
QQQ
715.830.35%
BTC/USD
78602.400.1903%
DIA
523.830.8%
GLD
403.851.03%
TLT
81.630.69%

Krystal Biotech Inc

KRYSNASDAQ
Trade with Public
Trade with Public
$353.90
2.640.75%
Last update: Sep 9, 3:00 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Krystal Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Krystal Biotech (KRYS).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

13Buy
Consensus RatingBuy# Analysts13Avg. Consensus PT$311Upside to Avg. PT-12.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026RBC CapitalLisa WalterInitiateOutperform$400
Aug 4, 2026CitigroupYigal NochomovitzPT RaiseBuy$378→$386
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $364 to $396.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403

TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $306 to $403.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361

HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $310 to $361.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $310 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved